Assessment of response to therapy in hepatocellular carcinoma

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The appropriate use of conventional or potential treatments for hepatocellular carcinoma requires that benefit can be shown. Therefore, the accurate assessment of response is both critical and essential. Demonstration of benefit observed will be determined by the criteria used. However, the use of conventional criteria based on anatomical imaging to assess response and progression is inadequate. Limitations occur due to the unique nature, presentation, and course of hepatocellular cancer, any underlying concomitant disease, the multiplicity of treatment options, and the challenges in assessing viable tumor. Locoregional therapies or cytostatic therapies can have beneficial effects and induce tumor necrosis without appreciable changes in tumor size. In recognition of the inherent limitations in conventional imaging criteria, various modifications have been proposed. In this review, the goals of assessing tumor response in clinical practice and in clinical trials are outlined. The varying patterns of response to different therapeutic modalities such as locoregional therapy and molecularly targeted therapy are reviewed, and an approach to the assessment of response based on clinical, biochemical, morphological, and functional criteria has been outlined. The implications of current and proposed approaches of assessing response for clinical practice or design of clinical trials are reviewed.

Original languageEnglish (US)
Pages (from-to)130-137
Number of pages8
JournalAnnals of Medicine
Volume46
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Clinical Trials
Therapeutics
Cytostatic Agents
Liver Neoplasms
Necrosis

Keywords

  • Clinical trials
  • Imaging
  • Liver cancer
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Assessment of response to therapy in hepatocellular carcinoma. / Patel, Tushar C; Harnois, Denise.

In: Annals of Medicine, Vol. 46, No. 3, 2014, p. 130-137.

Research output: Contribution to journalArticle

@article{942278906dff4a3bbc8cc757f2e4740f,
title = "Assessment of response to therapy in hepatocellular carcinoma",
abstract = "The appropriate use of conventional or potential treatments for hepatocellular carcinoma requires that benefit can be shown. Therefore, the accurate assessment of response is both critical and essential. Demonstration of benefit observed will be determined by the criteria used. However, the use of conventional criteria based on anatomical imaging to assess response and progression is inadequate. Limitations occur due to the unique nature, presentation, and course of hepatocellular cancer, any underlying concomitant disease, the multiplicity of treatment options, and the challenges in assessing viable tumor. Locoregional therapies or cytostatic therapies can have beneficial effects and induce tumor necrosis without appreciable changes in tumor size. In recognition of the inherent limitations in conventional imaging criteria, various modifications have been proposed. In this review, the goals of assessing tumor response in clinical practice and in clinical trials are outlined. The varying patterns of response to different therapeutic modalities such as locoregional therapy and molecularly targeted therapy are reviewed, and an approach to the assessment of response based on clinical, biochemical, morphological, and functional criteria has been outlined. The implications of current and proposed approaches of assessing response for clinical practice or design of clinical trials are reviewed.",
keywords = "Clinical trials, Imaging, Liver cancer, Magnetic resonance imaging",
author = "Patel, {Tushar C} and Denise Harnois",
year = "2014",
doi = "10.3109/07853890.2014.891355",
language = "English (US)",
volume = "46",
pages = "130--137",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Assessment of response to therapy in hepatocellular carcinoma

AU - Patel, Tushar C

AU - Harnois, Denise

PY - 2014

Y1 - 2014

N2 - The appropriate use of conventional or potential treatments for hepatocellular carcinoma requires that benefit can be shown. Therefore, the accurate assessment of response is both critical and essential. Demonstration of benefit observed will be determined by the criteria used. However, the use of conventional criteria based on anatomical imaging to assess response and progression is inadequate. Limitations occur due to the unique nature, presentation, and course of hepatocellular cancer, any underlying concomitant disease, the multiplicity of treatment options, and the challenges in assessing viable tumor. Locoregional therapies or cytostatic therapies can have beneficial effects and induce tumor necrosis without appreciable changes in tumor size. In recognition of the inherent limitations in conventional imaging criteria, various modifications have been proposed. In this review, the goals of assessing tumor response in clinical practice and in clinical trials are outlined. The varying patterns of response to different therapeutic modalities such as locoregional therapy and molecularly targeted therapy are reviewed, and an approach to the assessment of response based on clinical, biochemical, morphological, and functional criteria has been outlined. The implications of current and proposed approaches of assessing response for clinical practice or design of clinical trials are reviewed.

AB - The appropriate use of conventional or potential treatments for hepatocellular carcinoma requires that benefit can be shown. Therefore, the accurate assessment of response is both critical and essential. Demonstration of benefit observed will be determined by the criteria used. However, the use of conventional criteria based on anatomical imaging to assess response and progression is inadequate. Limitations occur due to the unique nature, presentation, and course of hepatocellular cancer, any underlying concomitant disease, the multiplicity of treatment options, and the challenges in assessing viable tumor. Locoregional therapies or cytostatic therapies can have beneficial effects and induce tumor necrosis without appreciable changes in tumor size. In recognition of the inherent limitations in conventional imaging criteria, various modifications have been proposed. In this review, the goals of assessing tumor response in clinical practice and in clinical trials are outlined. The varying patterns of response to different therapeutic modalities such as locoregional therapy and molecularly targeted therapy are reviewed, and an approach to the assessment of response based on clinical, biochemical, morphological, and functional criteria has been outlined. The implications of current and proposed approaches of assessing response for clinical practice or design of clinical trials are reviewed.

KW - Clinical trials

KW - Imaging

KW - Liver cancer

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84899810454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899810454&partnerID=8YFLogxK

U2 - 10.3109/07853890.2014.891355

DO - 10.3109/07853890.2014.891355

M3 - Article

VL - 46

SP - 130

EP - 137

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 3

ER -